Newco Linkgevity Ltd. has won backing from the KQ Labs accelerator program at the Francis Crick Institute in London, enabling it to take forward the lead program, an anti-necrotic drug for treating acute kidney injury, and to further develop its AI-driven system for identifying aging-related therapeutic targets. Alongside access to the Crick’s expertise in translational research and in shaping academic science to make it investible, companies joining KQ Labs receive an equity investment.

Newco Linkgevity Ltd. has won backing from the KQ Labs accelerator program at the Francis Crick Institute in London, enabling it to take forward the lead program, an anti-necrotic drug for treating acute kidney injury, and to further develop its AI-driven system for identifying aging-related therapeutic targets.

It has been previously demonstrated that necrosis is associated with metastatic dissemination of cancer cells; however, how necrosis promotes tumor dissemination is not understood. In a recent study, researchers from Fred Hutchinson Cancer Center and University of Washington aimed to investigate the correlation between tumor dissemination and the formation of large contiguous zones of necrosis within the tumor core.

Researchers led by Emanuel Hanski at the Hebrew University of Jerusalem have identified a class of molecules that inhibit endoplasmic reticulum (ER) stress and could decrease mortality in mice infected with Streptococcus pyogenes, also known as the group A streptococci.